Becton, Dickinson and Company
One Becton Drive
565 articles with Becton, Dickinson and Company
Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Company)
BD (Becton, Dickinson and Company) (NYSE: BDX) today issued the following statement regarding the sale of its Advanced Bioprocessing business to Thermo Fisher Scientific
BD (Becton, Dickinson and Company) announced today that it will present at the Morgan Stanley 2018 Global Healthcare Conference on Wednesday, September 12, 2018, at 11:40 a.m. ET.
BD Awards $1 Million in Grants to Help Community Health Centers Drive Effective Medication Use Among Vulnerable Patients
BD (Becton, Dickinson and Company), Direct Relief, and the National Association of Community Health Centers (NACHC) recently awarded five community health centers with a total of $1 million in grant funding, which will be used to expand programs that help vulnerable patients more effectively manage their medications.
BD (Becton, Dickinson and Company) announced today that it will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, September 5, 2018, at 3:00 PM ET.
Henderson, 53, is the non-executive chairman of the board of Qualcomm, Inc. and serves on the board of directors at FibroGen, Inc. and Halozyme Therapeutics, Inc. as well as serving as an advisory director to Berkshire Partners LLC.
As reported, revenues of $4.278 billion increased 41.0 percent.
BD (Becton, Dickinson and Company) appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.
BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis
BD® AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune System
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.75 per common share, payable on September 28, 2018 to holders of record on September 7, 2018.
BD (Becton, Dickinson and Company) issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company's 2020 Sustainability Goals.
everlinQ™ endoAVF System Receives FDA De Novo Marketing Authorization
BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its third fiscal quarter 2018 earnings conference call on Thursday, August 2, 2018, at 8:00 a.m. (ET).
The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.
BD, Helmer Scientific Collaborate to Introduce First Fully Integrated Refrigerated Automated Dispensing Solution
BD (Becton, Dickinson and Company) and Helmer Scientific announced a collaboration to introduce an industry-first, medical-grade refrigerated solution integrated with an automated dispensing system to provide clinicians secure, single line-item access to high-risk and high-value refrigerated medications.
BD (Becton, Dickinson and Company) announced that it will present at the several upcoming investor healthcare conferences.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer.
BD (Becton, Dickinson and Company) reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.
BD Launches BD FACSymphony™ High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types
BD (Becton, Dickinson and Company) announced the launch of the BD FACSymphony™ system, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell.
BD announced three executive appointments to the positions of segment president.